FDA 483 - Sichuan Huiyu Pharmaceutical Co., Ltd. - November 06, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Sichuan Huiyu Pharmaceutical Co., Ltd. revealed significant deficiencies across its quality control, laboratory, and production systems. The firm failed to adequately investigate and reject potentially contaminated batches, maintain proper environmental monitoring, and ensure equipment sanitation. Additionally, there were systemic issues with complaint handling, OOS investigations, and the completeness of batch production records, indicating a broad lack of adherence to cGMP regulations.
ID · 3810b919-5a63-46e1-bf2c-41c79bf175d7